• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

    2.395 -0.045 (-1.84%)
    Streaming Delayed Price Updated: 12:27 PM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 13,894
    Open 2.440
    Bid (Size) 2.370 (300)
    Ask (Size) 2.400 (100)
    Prev. Close 2.440
    Today's Range 2.395 - 2.440
    52wk Range 2.301 - 48.78
    Shares Outstanding 11,523,716
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
    From Aptevo Therapeutics
    Via ACCESS Newswire

    Performance

    YTD
    -74.5%
    -74.5%
    1 Month
    -39.4%
    -39.4%
    3 Month
    -54.3%
    -54.3%
    6 Month
    -66.2%
    -66.2%
    1 Year
    -91.7%
    -91.7%

    More News

    Read More
    News headline image
    Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
    From Aptevo Therapeutics
    Via ACCESS Newswire
    News headline image
    As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category
    Via NewMediaWire
    News headline image
    Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
    Via ACCESS Newswire
    News headline image
    Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
    Via ACCESS Newswire
    News headline image
    Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
    Via ACCESS Newswire
    News headline image
    Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment
    Via NewMediaWire
    News headline image
    Aptevo Provides State of the Business Report and 2025 Financial Results
    Via ACCESS Newswire
    News headline image
    Aptevo to Participate in March 2026 Conferences
    Via ACCESS Newswire
    Gapping stocks in Tuesday's session ↗
    Via Chartmill
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
    Via ACCESS Newswire
    News headline image
    Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
    Via ACCESS Newswire
    Friday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
    Via ACCESS Newswire
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Top movers in Friday's session ↗
    Via Chartmill
    News headline image
    Aptevo Therapeutics Stock Slumps To All-Time Low On Reverse Split Approval ↗
    Via Stocktwits
    News headline image
    Traders are paying attention to the gapping stocks in Friday's session. ↗
    Via Chartmill
    News headline image
    What's Going On With Aptevo Therapeutics Stock Today? ↗
    Via Benzinga
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Aptevo Therapeutics Inc. - Common Stock publicly traded?
    Yes, Aptevo Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Aptevo Therapeutics Inc. - Common Stock trade on?
    Aptevo Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aptevo Therapeutics Inc. - Common Stock?
    The ticker symbol for Aptevo Therapeutics Inc. - Common Stock is APVO on the Nasdaq Stock Market
    What is the current price of Aptevo Therapeutics Inc. - Common Stock?
    The current price of Aptevo Therapeutics Inc. - Common Stock is 2.395
    When was Aptevo Therapeutics Inc. - Common Stock last traded?
    The last trade of Aptevo Therapeutics Inc. - Common Stock was at 09/01/26 12:27 PM ET
    What is the market capitalization of Aptevo Therapeutics Inc. - Common Stock?
    The market capitalization of Aptevo Therapeutics Inc. - Common Stock is 27.60M
    How many shares of Aptevo Therapeutics Inc. - Common Stock are outstanding?
    Aptevo Therapeutics Inc. - Common Stock has 28M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.